These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 18154543)

  • 1. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenems: a potent class of antibiotics.
    Nicolau DP
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenems in the USA: focus on doripenem.
    Lister PD
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report.
    Berg ML; Crank CW; Philbrick AH; Hayden MK
    Ann Pharmacother; 2008 Feb; 42(2):207-12. PubMed ID: 18230703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative review of the carbapenems.
    Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
    Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.
    Behera B; Mathur P; Das A; Kapil A
    Singapore Med J; 2009 Jun; 50(6):628-32. PubMed ID: 19551319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
    Teng CP; Chen HH; Chan J; Lye DC
    Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P; Keel RA; Nicolau DP
    Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem.
    Goff DA; Mangino JE
    J Infect; 2008 Aug; 57(2):123-7. PubMed ID: 18644627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of cefepime and carbapenems in experimental pneumonia caused by porin-deficient Klebsiella pneumoniae producing FOX-5 beta-lactamase.
    Pichardo C; del Carmen Conejo M; Bernabéu-Wittel M; Pascual A; Jiménez-Mejías ME; de Cueto M; Pachón-Ibáñez ME; García I; Pachón J; Martínez-Martínez L
    Clin Microbiol Infect; 2005 Jan; 11(1):31-8. PubMed ID: 15649301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH).
    Lim CL; Lee W; Lee AL; Liew LT; Nah SC; Wan CN; Chlebicki MP; Kwa AL
    BMC Infect Dis; 2013 Nov; 13():523. PubMed ID: 24195651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.